1078 related articles for article (PubMed ID: 27913894)
1. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
3. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
4. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
[TBL] [Abstract][Full Text] [Related]
5. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
7. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
[TBL] [Abstract][Full Text] [Related]
10. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
Matsuno H; Katayama K
Mod Rheumatol; 2017 Mar; 27(2):246-251. PubMed ID: 27550060
[TBL] [Abstract][Full Text] [Related]
13. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
15. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
17. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]